Precigen Expects Q1 Revenue to Surpass $18 Million Due to Strong Uptake of Recurrent Respiratory Papillomatosis Drug

MT Newswires Live

04/07

Precigen (PGEN) said Tuesday it expects Q1 revenue to surpass $18 million due to the strong uptake of Papzimeos, its HPV-specific immunotherapy for the treatment of adults with recurrent respiratory papillomatosis.

The Centers for Medicare & Medicaid Services has also assigned J-code J3404 to the therapy effective April 1, which is set to streamline reimbursement and broaden its access, the company said.

Net product sales for the treatment in Q4 of 2025 were $3.4 million, with Precigen patient hub enrollment exceeding 300 due to physician and patient demand, the company said.

Precigen said it plans to launch a pediatric trial for the drug in Q4, as well as a study to evaluate the potential for redosing patients.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2625693726"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2625693726\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2625693726?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-07 19:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2625693726","market":"sg","top_or_hot":-1,"title":"Precigen Expects Q1 Revenue to Surpass $18 Million Due to Strong Uptake of Recurrent Respiratory Papillomatosis Drug","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/PGEN\">Precigen</a> (PGEN) said Tuesday it expects Q1 revenue to surpass $18 million due to the strong uptake of Papzimeos, its HPV-specific immunotherapy for the treatment of adults with recurrent respiratory papillomatosis.</p><p>The Centers for Medicare &amp; Medicaid Services has also assigned J-code J3404 to the therapy effective April 1, which is set to streamline reimbursement and broaden its access, the company said.</p><p>Net product sales for the treatment in Q4 of 2025 were $3.4 million, with Precigen patient hub enrollment exceeding 300 due to physician and patient demand, the company said.</p><p>Precigen said it plans to launch a pediatric trial for the drug in Q4, as well as a study to evaluate the potential for redosing patients.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Precigen Expects Q1 Revenue to Surpass $18 Million Due to Strong Uptake of Recurrent Respiratory Papillomatosis Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPrecigen Expects Q1 Revenue to Surpass $18 Million Due to Strong Uptake of Recurrent Respiratory Papillomatosis Drug\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-04-07 19:46</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/PGEN\">Precigen</a> (PGEN) said Tuesday it expects Q1 revenue to surpass $18 million due to the strong uptake of Papzimeos, its HPV-specific immunotherapy for the treatment of adults with recurrent respiratory papillomatosis.</p><p>The Centers for Medicare &amp; Medicaid Services has also assigned J-code J3404 to the therapy effective April 1, which is set to streamline reimbursement and broaden its access, the company said.</p><p>Net product sales for the treatment in Q4 of 2025 were $3.4 million, with Precigen patient hub enrollment exceeding 300 due to physician and patient demand, the company said.</p><p>Precigen said it plans to launch a pediatric trial for the drug in Q4, as well as a study to evaluate the potential for redosing patients.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PGEN","symbol_name":"Precigen","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2625693726","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2625693726","pubTimestamp":1775562366,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Precigen  said Tuesday it expects Q1 revenue to surpass $18 million due to the strong uptake of Papzimeos, its HPV-specific immunotherapy for the treatment of adults with recurrent respiratory papillomatosis.The Centers for Medicare & Medicaid Services has also assigned J-code J3404 to the therapy effective April 1, which is set to streamline reimbursement and broaden its access, the company said.Net product sales for the treatment in Q4 of 2025 were $3.4 million, with Precigen patient hub enrollment exceeding 300 due to physician and patient demand, the company said.Precigen said it plans to launch a pediatric trial for the drug in Q4, as well as a study to evaluate the potential for redosing patients.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"PGEN":"Precigen"},"translate_title":"由于复发性呼吸道乳头状瘤病药物的强劲吸收，Precigen预计第一季度收入将超过1800万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PGEN":1.5},"content_text":"Precigen (PGEN) said Tuesday it expects Q1 revenue to surpass $18 million due to the strong uptake of Papzimeos, its HPV-specific immunotherapy for the treatment of adults with recurrent respiratory papillomatosis.The Centers for Medicare & Medicaid Services has also assigned J-code J3404 to the therapy effective April 1, which is set to streamline reimbursement and broaden its access, the company said.Net product sales for the treatment in Q4 of 2025 were $3.4 million, with Precigen patient hub enrollment exceeding 300 due to physician and patient demand, the company said.Precigen said it plans to launch a pediatric trial for the drug in Q4, as well as a study to evaluate the potential for redosing patients.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}